Minimal residual disease in peripheral blood compared to bone marrow in patients treated for acute myeloid leukemia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON25015

Enrollment

151

Registered

2021-08-25

Start date

2021-08-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patient with: - a diagnosis of AML and related precursor neoplasms according to WHO 2008 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antecedent hematological disease (e.g. MDS) and therapy-related AML), or - acute leukemia’s of ambiguous lineage according to WHO 2008 or - a diagnosis of refractory anemia with excess of blasts (MDS) and IPSS-R score > 4.5. Treated according to HOVON clinical trials with intensive chemotherapy; Age 18 yr or older; A bone marrow aspiration has been scheduled; WHO performance status 0, 1 or 2; Written informed consent.

Exclusion criteria

Exclusion criteria: Pregnant or lactating females; Unwilling or not capable to use effective means of birth control.

Design outcomes

Primary

Measure	Time frame
The primary outcome measure is the prognostic value of (LSC) MRD in PB compared to BM for relapse free survival (RFS) and overall survival (OS).	—

Secondary

Measure	Time frame
Secondary outcome is to determine the correlation between MRD in PB and BM and determine the influence of dilution by comparing MRD percentage between the different BM tubes taken from one puncture and the PB sample.	—

Contacts

Public ContactJesse Tettero

Amsterdam UMC

j.tettero@amsterdamumc.nl0653516855

Outcome results